These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 24909571)

  • 1. Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy.
    Diotti RA; Mancini N; Clementi N; Sautto G; Moreno GJ; Criscuolo E; Cappelletti F; Man P; Forest E; Remy L; Giannecchini S; Clementi M; Burioni R
    Antiviral Res; 2014 Aug; 108():94-103. PubMed ID: 24909571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.
    Jelcic I; Combaluzier B; Jelcic I; Faigle W; Senn L; Reinhart BJ; Ströh L; Nitsch RM; Stehle T; Sospedra M; Grimm J; Martin R
    Sci Transl Med; 2015 Sep; 7(306):306ra150. PubMed ID: 26400911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab.
    Diotti RA; Capra R; Moiola L; Caputo V; De Rossi N; Sangalli F; Martinelli V; Burioni R; Clementi M; Mancini N
    Viruses; 2016 May; 8(5):. PubMed ID: 27164128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The human JC polyomavirus (JCPyV): virological background and clinical implications.
    Hirsch HH; Kardas P; Kranz D; Leboeuf C
    APMIS; 2013 Aug; 121(8):685-727. PubMed ID: 23781977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
    Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
    J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
    Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
    Prezioso C; Zingaropoli MA; Iannetta M; Rodio DM; Altieri M; Conte A; Vullo V; Ciardi MR; Palamara AT; Pietropaolo V
    Mult Scler Relat Disord; 2020 Jun; 41():102008. PubMed ID: 32087593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.
    Schwab N; Schneider-Hohendorf T; Wiendl H
    Int Immunol; 2015 Jan; 27(1):47-53. PubMed ID: 25326459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
    Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
    J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?
    Diotti RA; Nakanishi A; Clementi N; Mancini N; Criscuolo E; Solforosi L; Clementi M
    Clin Dev Immunol; 2013; 2013():967581. PubMed ID: 23878587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
    Sørensen PS; Bertolotto A; Edan G; Giovannoni G; Gold R; Havrdova E; Kappos L; Kieseier BC; Montalban X; Olsson T
    Mult Scler; 2012 Feb; 18(2):143-52. PubMed ID: 22312009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [[Natalizumab therapy, 2013].
    Karácsony M; Bencsik K; Vécsei L
    Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
    Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
    Baldwin KJ; Hogg JP
    Curr Opin Neurol; 2013 Jun; 26(3):318-23. PubMed ID: 23493158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody escape by polyomavirus capsid mutation facilitates neurovirulence.
    Lauver MD; Goetschius DJ; Netherby-Winslow CS; Ayers KN; Jin G; Haas DG; Frost EL; Cho SH; Bator CM; Bywaters SM; Christensen ND; Hafenstein SL; Lukacher AE
    Elife; 2020 Sep; 9():. PubMed ID: 32940605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of qPCR with ddPCR for the Quantification of JC Polyomavirus in CSF from Patients with Progressive Multifocal Leukoencephalopathy.
    Ngouth N; Monaco MC; Walker L; Corey S; Ikpeama I; Fahle G; Cortese I; Das S; Jacobson S
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis, natalizumab, and PML: helping patients decide.
    Rudick RA
    Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S18-23. PubMed ID: 22123928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-JC virus antibodies: implications for PML risk stratification.
    Gorelik L; Lerner M; Bixler S; Crossman M; Schlain B; Simon K; Pace A; Cheung A; Chen LL; Berman M; Zein F; Wilson E; Yednock T; Sandrock A; Goelz SE; Subramanyam M
    Ann Neurol; 2010 Sep; 68(3):295-303. PubMed ID: 20737510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients.
    Agostini S; Mancuso R; Costa AS; Caputo D; Clerici M
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33809082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.